Close Menu

NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2019 Q1 net loss rose about two percent year over year, as the firm nears the launch of its non-invasive lung cancer detection test, DetermaVu.

The liquid biopsy firm's net loss for the three months ended March 31, 2019 was $3.9 million, or $.08 per share, compared to a net loss of $3.8 million, or $.12 per share, in the same quarter last year, slightly beating the consensus Wall Street estimate of a loss of $.09 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.